Alexion Pharmaceuticalsの利益マージン
Alexion Pharmaceuticalsの利益マージンは何ですか。
Alexion Pharmaceuticals Inc.の利益マージンは10.89%です。
利益マージンの定義は何ですか。
利益マージンは、収益性の尺度であり、収益の割合として純利益を求めることによって計算されます。
Profit margin is calculated with the selling price (or revenue) taken as base times 100. It is the percentage of selling price that is turned into profit. Profit percentages are calculated to find the ratio of profit to cost of an investment. Profit margin is an indicator of a company's pricing strategies and how well it controls costs. Differences in competitive strategy and product mix cause the profit margin to vary among different companies. The profit margin is used mostly for internal comparisons. It is difficult to accurately compare the net profit ratio for different entities. Individual businesses' operating and financing arrangements vary so much that different entities are bound to have different levels of expenditure, so that comparison of one with another can have little meaning. A low profit margin indicates a low margin of safety: higher risk that a decline in sales will erase profits and result in a net loss, or a negative margin.
NASDAQのセクタHealth Careにおける利益マージンの企業と比べるAlexion Pharmaceuticals
Alexion Pharmaceuticalsは何をしますか。
Alexion is a global biopharmaceutical company focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. As a leader in rare diseases for more than 25 years, Alexion has developed and commercializes two approved complement inhibitors to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS), as well as the first and only approved complement inhibitor to treat anti-acetylcholine receptor (AchR) antibody-positive generalized myasthenia gravis (gMG) and neuromyelitis optica spectrum disorder (NMOSD). Alexion also has two highly innovative enzyme replacement therapies for patients with life-threatening and ultra-rare metabolic disorders, hypophosphatasia (HPP) and lysosomal acid lipase deficiency (LAL-D) as well as the first and only approved Factor Xa inhibitor reversal agent. In addition, the company is developing several mid-to-late-stage therapies, including a copper-binding agent for Wilson disease, an anti-neonatal Fc receptor (FcRn) antibody for rare Immunoglobulin G (IgG)-mediated diseases and an oral Factor D inhibitor as well as several early-stage therapies, including one for light chain (AL) amyloidosis, a second oral Factor D inhibitor and a third complement inhibitor. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.
Alexion Pharmaceuticalsと類似の利益マージン
- Unilever plcの利益マージンは10.88%です。
- Unilever Plcの利益マージンは10.88%です。
- Unilever NVの利益マージンは10.88%です。
- The Unileverの利益マージンは10.88%です。
- Gerdau S.Aの利益マージンは10.89%です。
- American Incの利益マージンは10.89%です。
- Alexion Pharmaceuticalsの利益マージンは10.89%です。
- Dollar Industriesの利益マージンは10.89%です。
- rhipeの利益マージンは10.89%です。
- Prudentialの利益マージンは10.90%です。
- PTBの利益マージンは10.90%です。
- Visionaryの利益マージンは10.90%です。
- Vidhi Specialty Food Ingredientsの利益マージンは10.91%です。